Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Congestive Heart Failure (CHF) Market Growth in 2025?

The market for congestive heart failure (CHF) has seen robust growth in recent times. The market, which currently stands at $15.94 billion in 2024, is expected to escalate to $17.10 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. Factors such as a higher prevalence of the aging population, an increase in cardiovascular diseases, heightened awareness about heart health, amplified healthcare spending, and blooming demand for remote patient monitoring are responsible for this historic period of growth.

What Is the Forecast for the Congestive Heart Failure (CHF) Market Size Through 2029?

In the forthcoming years, the market size of Congestive Heart Failure (CHF) is projected to experience robust expansion. The market is anticipated to reach $22.31 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.9%. The accelerating adoption of digital health technology, mounting prevalence of hypertension, escalating obesity rates, enhanced patient outcomes, and heightened emphasis on tailored medicine are among the reasons for the expansion in the forecast timeframe. Throughout the forecast timeframe, there will be significant trends such as advancements in diagnostic technology, progress in treatment methods, technological enhancements in medical imaging, innovations in therapeutic strategies, and advancements in wearable health technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp

What are the Key Market Players in Congestive Heart Failure (CHF) Market and How They’re Evolving?

Major companies operating in the congestive heart failure (CHF) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG., Medtronic Plc, Eli Lilly and Company, Canon Medical Systems Corporation, Novo Nordisk A/S, Jarvik Heart Inc., Boston Scientific Corporation, Applied Molecular Genetics Inc., Biotronik SE & Co. KG, Exelixis Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., LivaNova

What Are the Primary Growth Drivers in the Congestive Heart Failure (CHF) Market?

The surge in cases of cardiovascular diseases is anticipated to spur the development of the congestive heart failure (CHF) market. Cardiovascular concerns primarily involve the heart and blood vessels, underlining their function in blood circulation and overall health upkeep. The escalation in cardiovascular patients can be attributed to inactive lifestyles, poor nutrition, ageing demographics, and city life, thereby necessitating superior healthcare and treatment alternatives. Congestive heart failure (CHF) caters to cardiovascular patients by offering specialised treatments that boost heart performance, alleviate symptoms, and avert complications, thereby enriching patient care and overall health. For instance, the American College of Cardiology, a non-profit medical organization based in the US, reported an increase to 19.8 million cases of cardiovascular diseases in 2022, as of January 2023. Moreover, Eastern Europe has recorded the maximum death rate at 553 per 100,000. Hence, the rise in cardiovascular cases is fuelling the expansion of the congestive heart failure (CHF) market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp

What Are the Leading Segments in the Global Congestive Heart Failure (CHF) Industry?

The congestive heart failure (CHF) market covered in this report is segmented –

1) By Type: Systolic Heart Failure, Diastolic Failure, Left-Sided Heart Failure, Right-Sided Heart Failure

2) By Treatment: Medication, Surgery

3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings

Subsegments:

1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction

2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF)

3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure

4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure

What Are the Key Market Trends in the Congestive Heart Failure (CHF) Industry?

Prominent enterprises in the congestive heart failure (CHF) marketplace are gearing their efforts towards pioneering breakthroughs, such as singular intracoronary infusion treatments. These new treatment approaches are aimed at improving cardiac function and enhancing life quality for those afflicted with CHF. Singular intracoronary infusion is a procedure that administers medication directly into the coronary artery, targeting the heart for more specific treatment for conditions like CHF. For example, in January 2024, Bayer AG, based in Germany, and Asklepios Biopharmaceutical, Inc., a U.S. biotech firm, commenced the GenePHIT Phase II test for AB-1002, an exploratory gene therapy for CHF. This pioneering method uses a gene therapy strategy to tackle non-ischemic cardiomyopathy, offering a potential significant advancement in CHF treatment through cutting-edge genetic solutions. The trial employs an adaptive, double-blind, placebo-controlled methodology, and plans to recruit between 90 and 150 participants who have been medically stable for a minimum of four weeks and have a left ventricular ejection fraction ranging from 15% to 35%.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

What Is the Regional Outlook for the Congestive Heart Failure (CHF) Market?

North America was the largest region in the congestive heart failure (CHF) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (CHF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20730

This Report Delivers Insight On:

1. How big is the congestive heart failure (chf) market, and how is it changing globally?

2. Who are the major companies in the congestive heart failure (chf) market, and how are they performing?

3. What are the key opportunities and risks in the congestive heart failure (chf) market right now?

4. Which products or customer segments are growing the most in the congestive heart failure (chf) market?

5. What factors are helping or slowing down the growth of the congestive heart failure (chf) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model